KABRADGPharmaceuticals
Kabra Drugs Ltd — Cash Flow Statement
₹24.58
-3.19%
Kabra Drugs Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | -4.76 Cr | -0.21 Cr | -0.35 Cr | -0.13 Cr | — |
| Issuance Of Capital Stock | 24.66 Cr | 2.55 Cr | — | — | — |
| Capital Expenditure | -0.05 Cr | — | — | — | — |
| End Cash Position | 21.30 Cr | 2.67 Cr | 29496.00 | 12623.00 | — |
| Other Cash Adjustment Outside Changein Cash | 1000.00 | — | — | — | -1.00 |
| Beginning Cash Position | 2.67 Cr | 29000.00 | 12623.00 | 97826.00 | — |
| Changes In Cash | 18.63 Cr | 2.67 Cr | 16873.00 | -85203.00 | — |
| Financing Cash Flow | 23.39 Cr | 2.88 Cr | 0.36 Cr | 0.13 Cr | — |
| Net Common Stock Issuance | 24.66 Cr | 2.55 Cr | 0.00 | — | — |
| Common Stock Issuance | 24.66 Cr | 2.55 Cr | — | — | — |
| Net Issuance Payments Of Debt | -1.27 Cr | 0.33 Cr | 0.36 Cr | 0.13 Cr | — |
| Net Short Term Debt Issuance | -1.27 Cr | 0.33 Cr | 0.36 Cr | 0.13 Cr | — |
| Net Long Term Debt Issuance | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Investing Cash Flow | -0.05 Cr | 0.00 | 0.00 | 0.00 | — |
| Interest Received Cfi | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Business Purchase And Sale | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net PPE Purchase And Sale | -0.05 Cr | 0.00 | 0.00 | 0.00 | — |
| Operating Cash Flow | -4.71 Cr | -0.21 Cr | -0.35 Cr | -0.13 Cr | — |
| Taxes Refund Paid | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Change In Working Capital | -3.63 Cr | 0.53 Cr | -0.02 Cr | 0.04 Cr | — |
| Change In Other Current Liabilities | -1.64 Cr | 1.73 Cr | 0.00 | -0.08 Cr | — |
| Change In Other Current Assets | -1.99 Cr | -1.20 Cr | 0.00 | 0.00 | — |
| Change In Inventory | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Change In Receivables | 0.00 | 0.00 | 0.03 Cr | 0.65 Cr | — |
| Provisionand Write Offof Assets | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Depreciation And Amortization | 73000.00 | 0.00 | 0.00 | 99791.00 | — |
| Depreciation | 73000.00 | — | — | 99791.00 | 0.03 Cr |
| Gain Loss On Sale Of PPE | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income From Continuing Operations | -1.09 Cr | -0.74 Cr | -0.34 Cr | -0.19 Cr | — |
| Net Other Financing Charges | — | 2.55 Cr | — | — | — |
| Interest Paid Cff | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Investment Purchase And Sale | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Change In Payable | — | -1.73 Cr | -0.04 Cr | -0.53 Cr | -0.08 Cr |
| Repayment Of Debt | — | — | — | — | 0.00 |
| Long Term Debt Payments | — | — | — | — | 0.00 |
| Sale Of PPE | — | — | — | — | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Kabra Drugs Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.